RxDoctor Payments Data

Pei-Yuen Tang, DO

Family Medicine · Redlands, CANPI 1649243866

Payments from drug & device makers

$13,564in general payments, 2019–2025

Across 526 payments — averaging $25.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$2K
  • AstraZeneca$2K
  • AbbVie$1K
  • Bayer$826
  • Novo Nordisk$701
  • Corcept Therapeutics$608
  • plus $7K from 46 others

What the payments were for

  • Food & beverage$13,549100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,564 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$30,388
Medicare patients
99
Services billed
325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$86,426
JardianceEmpagliflozin79$70,189
OzempicSemaglutide33$57,461
TrulicityDulaglutide26$44,329
XareltoRivaroxaban27$27,861
JanuviaSitagliptin Phosphate24$26,473
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$24,855
RybelsusSemaglutide16$22,878
BelsomraSuvorexant16$9,510
BrilintaTicagrelor13$9,208
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$4,809
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen146$4,734
Humalog Kwikpen U-100Insulin Lispro13$4,404
Atorvastatin Calcium451$4,238
Gabapentin184$4,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$563$86,42671 claims
Novo NordiskOzempic, Rybelsus$701$80,34049 claims
Boehringer IngelheimJardiance, Stiolto Respimat$1,774$74,99890 claims
Lilly USA, LLCTrulicity$395$44,32926 claims
MerckJanuvia, Belsomra$275$35,98440 claims
GSKTrelegy Ellipta, Arnuity Ellipta$461$28,31242 claims
Johnson & JohnsonXarelto$133$27,86127 claims
AstraZenecaBrilinta$1,705$9,20813 claims
AbbVieSynthroid$1,163$3,08245 claims
Almatica Pharma LLCSertraline Hcl$97$1,81387 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Redlands

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →